Puma Biotechnology Inc (PBYI) Receives Analyst Rating

Puma Biotechnology Inc (PBYI) : 2 brokerage houses believe that Puma Biotechnology Inc (PBYI) is a Strong Buy at current levels. 3 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Puma Biotechnology Inc (PBYI). Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 5 Wall Street Analysts endorse the stock as a Buy with a rating of 2.2.

Puma Biotechnology Inc (PBYI) : The highest short term price target forecast on Puma Biotechnology Inc (PBYI) is $70 and the lowest target price is $36. A total of 4 equity analysts are currently covering the company. The average price of all the analysts is $56.75 with a standard deviation of $14.55.


Puma Biotechnology Inc (NYSE:PBYI): The stock opened in the green at $61.6 on Thursday, but the bulls found it difficult to push the prices higher. The stock reached a high of $61.75 and a low of $60.2 for the day. The stock did not find buyers even at the lows and closed at $60.57 recording a loss of -0.96%. 475,851 shares exchanged hands during the trading day. The stock had closed at $61.16 in the previous days trading.

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the acquisition, development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It licenses the rights to three drug candidates. It is developing PB272 (neratinib (oral)) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation. It is developing PB272 (neratinib (intravenous)) for the treatment of patients with advanced cancer. PB357 is an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.